news-24

Join Our Founder and CEO @ DCAT Week What: DCAT Member Company Announcement ForumWhen: 10:36-10:43AM, on Monday March 18, 2024Where: InterContinental Barclay, Grand Ballroom (2nd Floor) Porton Pharma Solutions Ltd (hereinafter referred to as Porton or the Company) will participate in the DCAT Week which will be held in New York, from March 18-21, 2024. […]

Porton Pharma Solutions Ltd. is thrilled to announce its commitment to climate action by joining the Science Based Targets initiative (SBTi). By aligning our emissions reduction targets with the Paris Agreement goals on limiting global warming to 1.5°C, we aim to contribute towards creating a sustainable and low-carbon future. By joining the SBTi, Porton commits

Farewell to 2023, and WE are Sailing forward to 2024 Year-end Review for 2023 Throughout 2023, despite myriad challenges, Porton stood united, striving, and collaborating as one Team. We are committed to developing our core CDMO business, continuously improve the EHS, Quality, and other support systems to lay a solid foundation for business development. In

The Pharma Crystallization Summit (PCS) is held annually to bring together developers of new medicines with crystallization challenges and the crystallization experts (solution providers) in the industry and academia. PCS programs are designed to stimulate in-depth discussions on common and/or leading bottleneck issues related to crystallization of drug substance (DS) as well as the intermediates,

The Pharma Crystallization Summit (PCS) is held annually to bring together developers of new medicines with crystallization challenges and the crystallization experts (solution providers) in the industry and academia. PCS programs are designed to stimulate in-depth discussions on common and/or leading bottleneck issues related to crystallization of drug substance (DS) as well as the intermediates, the

Porton Pharma Solutions Ltd. is glad to announce that it scored 38 (out of 100) in the 2023 S&P Global Corporate Sustainability Assessment reflecting an improvement of 9 points based on the 2023 methodology over the last year, where scores in all the three dimensions getting improved and exceeding the industry average. (CSA Score as

Porton Pharma Solutions has just opened its new drug development facility in Cranbury, New Jersey, operated under its US subsidiary J-Star Research. With over 40,000 square feet of floor space, this facility is customer built to provide world-leading services in API crystallization/isolation and drug product development from R&D to GMP delivery. It is adjacent to

In order to thoroughly implement General Secretary Xi Jinping’s important exposition on the development of digital economy, his spirit of sending congratulatory letters to the Smart China Expo three times, his vital instruction of “Continue to host high-standard Smart China Expo and deeply participate in international cooperation in the digital economy”, as well as the

Dear valued customers and partners, We would like to extend our gratitude for your continuous support towards Porton Pharma Solutions Ltd. In order to further enhance the company’s brand recognition, adapt to our global development strategy, improve communication efficiency, and protect each other’s information security, we have decided to change our email domain name from porton.cn to portonpharma.com.

Porton Pharma Solutions Ltd. continues to expand its reach globally. Last year, we launched the #construction of a new site in Menges, Slovenia. The state-of-the-art GMP #manufacturing site will significantly expand Porton’s #network beyond China and the US as it sets out to provide #solutions to customers and partners in #europe. Moreover, Porton also started